ECSP23054131A - Cocristal de un inhibidor de cdk - Google Patents

Cocristal de un inhibidor de cdk

Info

Publication number
ECSP23054131A
ECSP23054131A ECSENADI202354131A ECDI202354131A ECSP23054131A EC SP23054131 A ECSP23054131 A EC SP23054131A EC SENADI202354131 A ECSENADI202354131 A EC SENADI202354131A EC DI202354131 A ECDI202354131 A EC DI202354131A EC SP23054131 A ECSP23054131 A EC SP23054131A
Authority
EC
Ecuador
Prior art keywords
cocrystal
cdk inhibitor
relates
cdk7
disorders
Prior art date
Application number
ECSENADI202354131A
Other languages
English (en)
Inventor
Uday Bhat
Krishnaswamy Devanathan
Sangamesh Eshwarappa Badiger
Ranadeep Bokalial
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of ECSP23054131A publication Critical patent/ECSP23054131A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al compuesto de fumarato de fórmula (I) y su forma cristalina y métodos para su preparación. La invención también se relaciona con preparaciones adecuadas para usos farmacéuticos para el tratamiento de diversas enfermedades o trastornos mediados por CDK7, particularmente cáncer u otras enfermedades proliferativas.
ECSENADI202354131A 2020-12-18 2023-07-18 Cocristal de un inhibidor de cdk ECSP23054131A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18

Publications (1)

Publication Number Publication Date
ECSP23054131A true ECSP23054131A (es) 2023-09-29

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202354131A ECSP23054131A (es) 2020-12-18 2023-07-18 Cocristal de un inhibidor de cdk

Country Status (17)

Country Link
US (1) US20240059669A1 (es)
EP (1) EP4263534A1 (es)
JP (1) JP2023554492A (es)
KR (1) KR20230159363A (es)
CN (1) CN116685326A (es)
AU (1) AU2021402415A1 (es)
CA (1) CA3202198A1 (es)
CL (1) CL2023001753A1 (es)
CO (1) CO2023009368A2 (es)
CR (1) CR20230261A (es)
DO (1) DOP2023000126A (es)
EC (1) ECSP23054131A (es)
IL (1) IL303738A (es)
MX (1) MX2023007218A (es)
PE (1) PE20231441A1 (es)
TW (1) TW202241881A (es)
WO (1) WO2022130304A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180041112A (ko) 2015-06-04 2018-04-23 오리진 디스커버리 테크놀로지스 리미티드 Cdk 억제제로서의 치환된 헤테로사이클릴 유도체

Also Published As

Publication number Publication date
EP4263534A1 (en) 2023-10-25
AU2021402415A1 (en) 2023-07-06
US20240059669A1 (en) 2024-02-22
CL2023001753A1 (es) 2024-02-02
DOP2023000126A (es) 2023-11-30
CN116685326A (zh) 2023-09-01
JP2023554492A (ja) 2023-12-27
CO2023009368A2 (es) 2023-09-29
KR20230159363A (ko) 2023-11-21
CR20230261A (es) 2023-10-04
CA3202198A1 (en) 2022-06-23
TW202241881A (zh) 2022-11-01
PE20231441A1 (es) 2023-09-14
IL303738A (en) 2023-08-01
WO2022130304A1 (en) 2022-06-23
MX2023007218A (es) 2023-07-27

Similar Documents

Publication Publication Date Title
BR112022010383A2 (pt) Compostos tricíclicos substituídos
BR112022012641A2 (pt) Compostos tricíclicos substituídos
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
CR20190124A (es) Inhibidores de ssao de aminopirimidina
WO2018198077A3 (en) 6-6 FUSIONED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS INHIBITORS OF LATS
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
CU24671B1 (es) Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
ECSP23054131A (es) Cocristal de un inhibidor de cdk
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
BR112021011325A2 (pt) Derivados de rapamicina